Teva Pharmaceuticals (TEVA -2.22%) is often referred to as the biggest generic drugmaker in the world, and its 2.8% dividend yield can look attractive to investors seeking health care exposure in their portfolio. However, the company is facing many headwinds in the coming years. Its top-selling multiple sclerosis drug Copaxone, for instance, is not a generic product and is facing upcoming roadblocks that could stall the company's growth. In the following video, health care analyst Max Macaluso elaborates on the three biggest challenges Teva is facing today.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.